Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07001254 · ClinicalTrials.gov registry record · Phase 2
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
A Phase 2 study, sponsored by Anjali Sharathkumar.
- Not yet
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07001254 is a Phase 2 study that has not yet begun recruiting, run by Anjali Sharathkumar. The registered enrollment target is 15 participants.
The verdict
NCT07001254, a Phase 2 study, has not yet begun recruiting, sponsored by Anjali Sharathkumar.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment naïve and relapsed/refractory, in inducing trilineage hematopoiesis in children and young adults.
Interventions
- DRUG Romiplostim
- DRUG Immunosuppressive therapy (IST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07001254
The ClinicalTrials.gov registry entry for NCT07001254 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anjali Sharathkumar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Romiplostim is the first listed.
NCT07001254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07001254 about?
NCT07001254 is a clinical study titled "UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia". This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment naïve and relapsed/refractory, in inducing trilineage hematopoiesis in children and young adults.
What is the current status of trial NCT07001254?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-08-01. Estimated completion is 2031-12-31.
What interventions are being tested in trial NCT07001254?
The interventions under investigation include: Romiplostim (DRUG), Immunosuppressive therapy (IST) (DRUG).
Who is sponsoring clinical trial NCT07001254?
This trial is sponsored by Anjali Sharathkumar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.